UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 11, 2015
Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware |
|
000-30929 |
|
13-4087132 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act. |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers
Keryx Biopharmaceuticals, Inc. announced on January 11, 2015, it will be
transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison. Mr. Bentsur has led Keryx for the past 5 years, culminating in U.S. Food and Drug Administration approval and year-end 2014
launch of Auryxia (ferric citrate). Mr. Madison joined Keryx in February 2014 as Chief Operating Officer to transition the Company from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth
of relevant expertise in both the phosphate binder and iron deficiency anemia markets. Mr. Madison has been appointed President of Keryx and will work with Mr. Bentsur to ensure a successful leadership transition by the end of May, when
Mr. Bentsurs contract expires. A copy of the press release is being filed as Exhibit 99.1.
Item 9.01 |
Financial Statements And Exhibits. |
|
|
|
99.1 |
|
Keryx Biopharmaceuticals, Inc. Press Release, dated January 11, 2015. |
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Keryx Biopharmaceuticals, Inc. |
|
|
|
|
(Registrant) |
|
|
|
|
Date: January 12, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ James F. Oliviero |
|
|
|
|
|
|
James F. Oliviero |
|
|
|
|
|
|
Chief Financial Officer |
- 3 -
INDEX TO EXHIBITS
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Keryx Biopharmaceuticals, Inc. Press Release, dated January 11, 2015. |
- 4 -
Exhibit 99.1
Keryx Biopharmaceuticals Announces Transition of Leadership
~The Role of Chief Executive Officer Transitioning from Ron Bentsur to Greg Madison~
New York, NY and Boston, MA January 11, 2015 Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the Company) today announced it
will be transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison. Mr. Bentsur has led Keryx for the past 5 years, culminating in U.S. Food and Drug Administration approval and
year-end 2014 launch of Auryxia (ferric citrate). Mr. Madison joined Keryx in February 2014 as Chief Operating Officer to transition the Company from a development-stage organization into a fully integrated commercial entity, bringing to
Keryx a wealth of relevant expertise in both the phosphate binder and iron deficiency anemia markets. Mr. Madison has been appointed President of Keryx and will work with Mr. Bentsur to ensure a successful leadership transition by the end
of May, when Mr. Bentsurs contract expires.
It has been a privilege to lead Keryx for the past 5 years through the approval and year-end
launch of Auryxia and I thank all of our employees for their tremendous dedication and commitment to position Keryx for future success, said Ron Bentsur, Chief Executive Officer of Keryx. With Keryxs focus having shifted from
development to a commercial enterprise, it is a logical point in the evolution of the Company for a change in leadership and Greg and I will work closely over the coming months to ensure a smooth transition. I have the utmost confidence in
Gregs ability to take Keryx to the next level.
I am truly excited about being asked to lead Keryx at this important stage of our
Companys evolution, said Mr. Madison. With an exceptional team in place, a truly differentiated product, and a deep-rooted commitment to the renal community, I am confident that we will build a leading renal franchise,
delivering value to all stakeholders patients, physicians, providers, employees and our shareholders.
On behalf of the entire Keryx
Board, I want to thank Ron for his years of service to Keryx, his leadership of this organization, his commitment and drive to the successful development and approval of Auryxia, and his contributions to the Companys Board of Directors,
stated Michael Tarnok, Chairman of Keryxs Board of Directors. Greg has done an outstanding job building the organization and readying us for Auryxias launch in a very short period of time. We are confident that the combination of
his leadership skills and experience, particularly at Genzyme where he ran the renal division, makes Greg the ideal leader for Keryx as we continue to build a world-class renal company.
Prior to joining Keryx, Mr. Madison served as the Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals where he led the team to
significant growth in net revenues. Prior to AMAG, Mr. Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership,
culminating in his most recent role as Vice President and General Manager of the Renal division. In this role, Mr. Madison led a global organization with three marketed products with combined revenues exceeding $1 billion.
Mr. Madisons prior experience in the Renal division included serving as Vice President and General Manager of the U.S. business; Vice President of U.S. sales; and Vice President of U.S. marketing where he led all pre-launch preparation
for Renvela®.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company
launched its first FDA-approved product, Auryxia, in the United States in December 2014. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as
Riona® by Keryxs Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. For more information about Keryx, please visit www.keryx.com.
Page 1 of 2
Cautionary Statement
Some of the statements included in this press release, particularly those regarding the commercialization and subsequent clinical development of Auryxia, may
be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among
the factors that could cause our actual results to differ materially are the following: whether Auryxia will be successfully launched and marketed in the U.S.; whether Riona® will be successfully marketed by our Japanese partner, Japan
Tobacco, Inc. and Torii Pharmaceutical Co., Ltd; the risk that the EMA may not concur with our interpretation of our registration studies in ESRD and non-dialysis dependent chronic kidney disease, supportive data, conduct of the studies,
or any other part of our MAA submission and could ultimately deny approval of the MAA; the risk that we may not be successful in the development of ferric citrate for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease
patients; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We
do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our
website is not incorporated by reference into this press release and is included for reference purposes only.
KERYX CONTACT:
Amy Sullivan, Vice President Corporate Development and Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447 or 508-479-3480
E-mail: amy.sullivan@keryx.com
Page 2 of 2
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024